AP NEWS

High Mobility Group Protein B1 - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 18, 2018

DUBLIN--(BUSINESS WIRE)--Sep 18, 2018--The “High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.The report outlays comprehensive information on the High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.The report covers products from therapy areas Central Nervous System, Infectious Disease, Cardiovascular, Oncology, Dermatology, Gastrointestinal, Hematological Disorders, Immunology, Respiratory and Toxicology which include indications Sepsis, Parkinson’s Disease, Traumatic Brain Injury, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Autoimmune Disorders, Cerebral Infarction (Brain Infarction), Chemotherapy Effects, Epidermolysis Bullosa, Epilepsy, Idiopathic Pulmonary Fibrosis, Inflammation, Influenzavirus A Infections, Liver Diseases, Myelodysplastic Syndrome, Neuropathic Pain (Neuralgia), Neutropenia, Refractory Acute Myeloid Leukemia, Stroke and Thrombocytopenia.

Furthermore, this report also reviews key players involved in therapeutics development with respective active and dormant or discontinued projects.

Companies Featured

Affibody ABCantex Pharmaceuticals Inc.Evec Inc.Ribomic Inc.Shionogi & Co. Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/95jr3z/high_mobility?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005527/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/18/2018 07:58 AM/DISC: 09/18/2018 07:58 AM

http://www.businesswire.com/news/home/20180918005527/en

AP RADIO
Update hourly